Fig. 6

Prognosis for our cases. The mean/median PFS were 70.4/27.6 months for ependymomas, ZFTA::RELA fusion-positive, 36.3/not reached months for ependymomas, YAP1 fusion-positive, 24.4/9.2 months for ependymomas, ZFTA non-RELA fused, and 43.9/34.0 months for astroblastomas, MN1-altered, 16.2/12.0 for CNS tumors with BCOR internal tandem duplication and 182.2/277 months for NET PLAGL1 with a significant difference in univariate analysis (p < 0.001). The median OS was not reached for all subgroups except CNS tumors with BCOR internal tandem duplication (76.0 months) and the mean OS was not reached for the ependymomas, YAP1 fusion-positive. The mean OS were 113.5 months for ependymomas, ZFTA::RELA fusion-positive, 39.3 months for ependymomas, ZFTA non-RELA fused, 81.6 months for astroblastomas, MN1-altered, 53.2 months for CNS tumors with BCOR internal tandem duplication and 111.0 months for NET PLAGL1 with a significant difference in univariate analysis (p = 0.002)